New Hsp90 Inhibitors to Treat Life-threatening or Resistant Prostate Cancer

10 May

A recent study showed that when the time for aggressive prostate cancer resistant to conventional treatment of patients most likely to benefit from the new treatment in a class of cancer drugs.
New Hsp90 Inhibitors to Treat Life-threatening or Resistant Prostate Cancer
The researchers found that a class of drugs called Hsp90 inhibitor can specifically malignant tumor cells in prostate cancer cell activity and reduce resistance to standard treatment drugs.

The study provides important information to enable researchers informed of Hsp90 drug-resistant prostate cancer in the role, and by inhibiting the activity of a protein associated with prostate cancer treatment provides a new way to the clinician.

Team at the London Cancer Society study found that Hsp90 inhibitors can relieve the inhibition of androgen receptor suffered, and hormone-refractory prostate cancer androgen receptor is usually suppressed.

Studies have shown that, Hsp90 inhibitors for those who are already resistant to the effects of hormone therapy to treat prostate cancer have a good effect. The study, published in the journal Cancer Research.

Hsp90 receptor inhibitors is a new type of drug, it can destroy a number of different proteins that directly attack tumor cells, effect on tumor cell growth and survival, making it difficult for them to escape the killing effect of traditional treatment. Therefore, this new drug is also not referred to as “resistance breaker.”

The new study found, Hsp90 inhibitors may also block the androgen receptor abnormalities in the form of production, impair tumor cell resistance to hormone therapy.

Prostate tumors grown to rely on androgen spread, therefore, block androgen that experience is an effective treatment. However, tumor cells often causes abnormal androgen receptor forms generated, so that these receptors without being stimulated androgen also meet the growth requirements of tumor cells.

The researchers investigated the role of Hsp90 inhibitors in human tumor cells, they found that the most common cause of androgen receptor mutation, becoming AR-V7. Researchers in the laboratory cultured tumor cells, and injected them into mice.

The researchers found that Hsp90 inhibitors work by reducing the cause for a new kind of unexpected form AR-V7 generation – changed the messenger RNA processing AR-V7 coding.

Hsp90 inhibitors may also reduce normal androgen receptor level, the decrease in prostate cancer is important molecules such as AKT and GR.

Professor Paul Workman study jointly responsible for one of the people is the chief manager of the Center for Cancer Research in London, he thought Hsp90 is a “net effect of the drug”, because “Hsp90 unlike other drugs with only a single signaling pathway and rely on this ways for treatment, while Hsp90 may target multiple signaling pathways of tumor cells and simultaneously interference, while the tumor to attack from a number of ways. than only for a single type of protein treatment, the drug can cause tumors more major damage, and can prevent and overcome resistance in prostate cancer. ”

Study co-leader Professor Johann de Bono said:. “We first prove that Hsp90 inhibitors can organize the most common abnormality of the androgen receptor to produce the kind of abnormal receptors may cause prostate cancer to present a variety of new drug therapies have lost the corresponding clinical trials, and I was most exciting thing is that the new drugs so that those who exhausted all treatment patients still can not get better again saw hope. “